5/29
08:12 am
mdgl
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress [Yahoo! Finance]
5/29
08:00 am
mdgl
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
Low
Report
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
5/21
09:51 am
mdgl
Is Madrigal Pharmaceuticals Stock a Buy? [Yahoo! Finance]
Medium
Report
Is Madrigal Pharmaceuticals Stock a Buy? [Yahoo! Finance]
5/16
08:25 am
mdgl
Paulson & Co's top buy and sells in Q1 [Seeking Alpha]
Low
Report
Paulson & Co's top buy and sells in Q1 [Seeking Alpha]
5/10
09:33 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at B. Riley from $270.00 to $200.00. They now have a "neutral" rating on the stock.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at B. Riley from $270.00 to $200.00. They now have a "neutral" rating on the stock.
5/8
03:33 pm
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at Citigroup Inc. from $389.00 to $382.00. They now have a "buy" rating on the stock.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at Citigroup Inc. from $389.00 to $382.00. They now have a "buy" rating on the stock.
5/8
03:32 pm
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at HC Wainwright from $425.00 to $390.00. They now have a "buy" rating on the stock.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at HC Wainwright from $425.00 to $390.00. They now have a "buy" rating on the stock.
5/8
02:42 pm
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at JMP Securities from $397.00 to $381.00. They now have a "market outperform" rating on the stock.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at JMP Securities from $397.00 to $381.00. They now have a "market outperform" rating on the stock.
5/7
07:16 am
mdgl
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Medium
Report
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
5/7
07:00 am
mdgl
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
Medium
Report
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
4/30
04:42 pm
mdgl
Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label [Seeking Alpha]
Medium
Report
Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label [Seeking Alpha]
4/24
04:00 pm
mdgl
Madrigal Statement on the Passing of Dr. Stephen Harrison
Medium
Report
Madrigal Statement on the Passing of Dr. Stephen Harrison
4/24
01:16 pm
mdgl
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage [Seeking Alpha]
Low
Report
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage [Seeking Alpha]
4/23
08:12 am
mdgl
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 [Yahoo! Finance]
4/23
08:00 am
mdgl
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Low
Report
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
4/22
08:09 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $150.00 price target on the stock.
Medium
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $150.00 price target on the stock.
4/16
04:05 pm
mdgl
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/12
02:04 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
4/10
10:26 am
mdgl
2 Under-the-Radar Growth Stocks to Consider [Yahoo! Finance]
Low
Report
2 Under-the-Radar Growth Stocks to Consider [Yahoo! Finance]
4/9
08:13 am
mdgl
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis [Yahoo! Finance]
4/9
08:00 am
mdgl
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Medium
Report
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
4/5
09:19 am
mdgl
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) [Yahoo! Finance]
Low
Report
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) [Yahoo! Finance]
4/3
04:05 pm
mdgl
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/3
08:51 am
mdgl
1 No-Brainer Growth Stock to Buy Now [Yahoo! Finance]
Low
Report
1 No-Brainer Growth Stock to Buy Now [Yahoo! Finance]
3/29
04:54 am
mdgl
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? [Yahoo! Finance]
Medium
Report
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? [Yahoo! Finance]